{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Low-dose LSD has real measurable effects, but sustained depression/anxiety relief from repeated microdosing remains unconfirmed beyond expectancy and concurrent care.",
  "implications": "Primary-subclaim aggregation returns SC2 Γ. Controlled acute drug action and direct exploratory MDD improvement provide partial support, while a now verified masked clinical conference report is primary-null. Neither healthy nulls nor a single imprecise conference result establish universal inefficacy, and the open-label positive cannot override the clinical comparator. Full-dose and ketamine results retain their actual scopes.",
  "limitations": "64 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}